1. Home
  2. HRMY vs CLVT Comparison

HRMY vs CLVT Comparison

Compare HRMY & CLVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Harmony Biosciences Holdings Inc.

HRMY

Harmony Biosciences Holdings Inc.

HOLD

Current Price

$32.44

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Logo Clarivate Plc

CLVT

Clarivate Plc

HOLD

Current Price

$2.84

Market Cap

1.7B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
HRMY
CLVT
Founded
2017
2016
Country
United States
United Kingdom
Employees
N/A
12000
Industry
Biotechnology: Pharmaceutical Preparations
EDP Services
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.7B
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
HRMY
CLVT
Price
$32.44
$2.84
Analyst Decision
Buy
Hold
Analyst Count
9
7
Target Price
$44.11
$3.22
AVG Volume (30 Days)
799.5K
5.2M
Earning Date
05-07-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
7.97
N/A
EPS
2.71
N/A
Revenue
$868,453,000.00
N/A
Revenue This Year
$19.75
N/A
Revenue Next Year
$12.88
$2.12
P/E Ratio
$11.72
N/A
Revenue Growth
21.51
N/A
52 Week Low
$25.52
$1.66
52 Week High
$40.87
$4.77

Technical Indicators

Market Signals
Indicator
HRMY
CLVT
Relative Strength Index (RSI) 66.25 60.97
Support Level $32.13 $2.29
Resistance Level $33.21 $3.73
Average True Range (ATR) 1.32 0.20
MACD 0.19 0.03
Stochastic Oscillator 58.88 68.66

Price Performance

Historical Comparison
HRMY
CLVT

About HRMY Harmony Biosciences Holdings Inc.

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

About CLVT Clarivate Plc

Clarivate is a data, information, and software workflow solutions company serving customers primarily in academia, government, law, life sciences, and healthcare. The company was formerly part of Thomson Reuters before being sold to private equity as an independent company in 2016. In 2019, Clarivate went public on the New York Stock Exchange. Around half of the company's revenue is generated in the Americas, while Europe, Middle East, and Africa account for around a quarter.

Share on Social Networks: